- Pressemitteilung BoxID 544940
Ypsomed doubles dividends to shareholders
The shareholders approved all amendments to the statutes that were mainly required by the Ordinance Against Excessive Compensation in Swiss Listed Companies. The directors, Dr. h.c. Willy Michel, Anton Kräuliger, Prof. em. Norbert Thom and Gerhart Isler, have been reelected to their offices for one year until the next regular annual general meeting. Dr. h.c. Willy Michel was approved as president of the board of directors for the same period. For the first time, the shareholders also decided on the remuneration for the board of directors and management. They approved the respective proposals of the board of directors.
The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, autoimmune diseases, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.
Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.
Diese Pressemitteilungen könnten Sie auch interessieren
Mit dem neu verabschiedeten Betriebsrentenstärkungsgesetz (BRSG) soll die Betriebsrente attraktiver werden – allerdings mit einem Nachteil für...
Riester-Sparer sollten ihren Vertrag einmal jährlich prüfen. Denn jegliche Gehaltserhöhung, auch per Tarifabschluss oder Berufsgruppensprung,...